Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Lifestyle Press Releases.
Press releases published on May 8, 2025

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …

Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical …

Varonis to Present at Upcoming Investor Conferences
MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its participation at the following upcoming conferences: The J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference …

Titan Machinery Inc. to Report Fiscal First Quarter Ended April 30, 2025 Results on Thursday, May 22, 2025
WEST FARGO, N.D., May 08, 2025 (GLOBE NEWSWIRE) -- Titan Machinery Inc. (Nasdaq: TITN), a leading network of full-service agricultural and construction equipment stores, announced today it will release financial results for the first quarter April 30, 2025 …

Fulcrum Therapeutics to Participate in Upcoming May Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …

Cytek Biosciences Reports First Quarter 2025 Financial Results
FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First …

Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025
Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway …

Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with …

Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data …

Lantronix Reports Results for Third Quarter of Fiscal 2025
Third Quarter Net Revenue of $28.5 Million Third Quarter GAAP EPS of ($0.10) Third Quarter Non-GAAP EPS of $0.03 IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity for the Internet of …

The RealReal Announces First Quarter 2025 Results
Q1 2025 Revenue of $160 million, up 11% Year-Over-Year Q1 2025 Net Income of $62 million including $80 million of non-cash gains Q1 2025 Adjusted EBITDA of $4.1 million improved $6.4 million Year-Over-Year SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- …

Brilliant Earth Announces Participation in B. Riley Securities 25th Annual Investor Conference
SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (NASDAQ: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced that the Company will participate in the B. …

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …

FAT BRANDS INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Conference call and webcast today at 5:30 p.m. ET LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) -- FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”) today reported financial results for the fiscal first quarter ended …

Texas Roadhouse, Inc. Announces First Quarter 2025 Results
LOUISVILLE, KY., May 08, 2025 (GLOBE NEWSWIRE) -- Texas Roadhouse, Inc. (NasdaqGS: TXRH), today announced financial results for the 13 weeks ended April 1, 2025. Financial Results Financial results for the 13 weeks ended April 1, 2025 and March 26, 2024 …

Nanox to Report First Quarter 2025 Financial Results on May 22, 2025
PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Metsera to Present at Bank of America 2025 Global Healthcare Conference
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit …

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in …

Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter …